ESMO 2021: Phase 2 Study of Belzutifan (MK-6482), an Oral Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor, Plus Cabozantinib for Treatment of Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Phase 3 Study to Evaluate HIF-2α Inhibitor in RCC - Cancer Therapy Advisor
PT2977 is an Orally Active and Selective HIF-2α Inhibitor for Solid Tumor Treatment - Network of Cancer Research
Mutual Antagonism of Hypoxia-Inducible Factor Isoforms in Cardiac, Vascular, and Renal Disorders | JACC: Basic to Translational Science
HIF-2 heterodimerization inhibitors (a) structure of a HIF-2aPAS B... | Download Scientific Diagram
New Drugs Show Potential Against Kidney Cancer - NCI
Combination between HIF-2α inhibitor, MK-6482 and cabozantinib is highlighted in ASCO GU 2021 - Onco Americas
Hypoxia-inducible factor-2 alpha promotes the proliferation of human placenta-derived mesenchymal stem cells through the MAPK/ERK signaling pathway | Scientific Reports
ASCO GU 2021: Phase 2 Study of the Oral Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor MK-6482 in Combination with Cabozantinib in Patients with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
Discovery of a Potent and Orally Bioavailable Hypoxia-Inducible Factor 2α ( HIF-2α) Agonist and Its Synergistic Therapy with Prolyl Hydroxylase Inhibitors for the Treatment of Renal Anemia | Journal of Medicinal Chemistry
Targeting HIF2α-ARNT hetero-dimerisation as a novel therapeutic strategy for pulmonary arterial hypertension | European Respiratory Society
New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas in: Endocrine-Related Cancer Volume 24 Issue 9 (2017)
HIF stabilization by prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease
A central role for hypoxia-inducible factor (HIF)-2α in hepatic glucose homeostasis - IOS Press
Mechanism of action of the HIF inhibitors, blocking different steps of... | Download Scientific Diagram
Development of inhibitors of the PAS-B domain of the HIF-2α transcription factor. | Semantic Scholar
Merck's VHL Drug Becomes First-Ever HIF-2α Inhibitor Approved in U.S. | BioSpace
New HIF2α inhibitors: potential implications as therapeutics for advanced pheochromocytomas and paragangliomas in: Endocrine-Related Cancer Volume 24 Issue 9 (2017)
HIF-2alpha: Achilles' heel of pseudohypoxic subtype paraganglioma and other related conditions - ScienceDirect
Design and Activity of Specific Hypoxia-Inducible Factor-2α (HIF-2α) Inhibitors for the Treatment of Clear Cell Renal Cell Carcinoma: Discovery of Clinical Candidate (S)-3-((2,2-Difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5 ...
Passing the baton: the HIF switch: Trends in Biochemical Sciences
HIF2α: a new therapeutic target for NAFLD | Nature Reviews Gastroenterology & Hepatology
Is HIF activation Janus faced? The therapeutic effects of the HIF-2α inhibitor - Kidney International
Preferential inhibitory effects on HIF-1α and HIF-2α in hypoxia... | Download Scientific Diagram
